Anzeige
Meldung des Tages: Bohrtreffer, Infrastruktur, Finanzierung: Beginnt hier der Weg zur Produktion?

Protalix News

Aktie
WKN:  A2PWSL ISIN:  US74365A3095 US-Symbol:  PLX Branche:  Biotechnologie Land:  USA
2,30 $
+0,00 $
0,00%
1,9523 € 00:30:00 Uhr
Depot/Watchlist
Marktkapitalisierung *
113,21 Mio. €
Streubesitz
72,33%
KGV
47
Index-Zuordnung
-

Protalix BioTherapeutics News

18.03.26 - PR Newswire
Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results
Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results PR Newswire
11.03.26 - PR Newswire
Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026
Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026 PR Newswire
05.01.26 - PR Newswire
Protalix BioTherapeutics Letter to Stockholders
Protalix BioTherapeutics Letter to Stockholders PR Newswire
17.12.25 - PR Newswire
Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement
Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement PR Newswire
13.11.25 - PR Newswire
Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results
Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results PR Newswire
06.11.25 - PR Newswire
Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025
Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025 PR Newswire
28.10.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX PR Newswire
23.10.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX PR Newswire
02.09.25 - PR Newswire
Protalix BioTherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Protalix BioTherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference PR Newswire
14.08.25 - PR Newswire
Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results
Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results PR Newswire
07.08.25 - PR Newswire
Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025
Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025 PR Newswire
21.07.25 - PR Newswire
Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer
Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer PR Newswire
30.06.25 - PR Newswire
Protalix BioTherapeutics Added to Russell 3000® and 2000 Indexes®
Protalix BioTherapeutics Added to Russell 3000® and 2000 Indexes® PR Newswire
14.05.25 - PR Newswire
Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC
Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC PR Newswire
09.05.25 - PR Newswire
Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results
Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results PR Newswire
05.05.25 - PR Newswire
Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025
Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025 PR Newswire

Newssuche

Videos

newspaper
16.04.26 +0,41%
Technical Trading: Treffsichere Signale für Gold
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »